Regulatory 2025-02-12 | Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-01-30 | NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
2025-01-27 | Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting PDF Report Presentation Webcast
2024-12-23 | Ascelia Pharma Patent Granted in China for Second Generation Orviglance PDF Report Presentation Webcast
2024-12-17 | Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025 PDF Report Presentation Webcast
2024-12-02 | Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting PDF Report Presentation Webcast
2024-11-06 | Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE PDF Report Presentation Webcast
Regulatory 2024-10-30 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 30 October 2024 PDF Report Presentation Webcast
2024-10-24 | Ascelia Pharma Presents Late-Breaking Abstract on SPARKLE Data at the American Society of Nephrology Kidney Week Congress 2024 PDF Report Presentation Webcast
Regulatory 2024-10-04 | Notice of Extraordinary General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-10-04 | Ascelia Pharma Announces Proposal for Election of Marianne Kock as New Member of the Board of Directors PDF Report Presentation Webcast
2024-09-30 | Ascelia Pharma Finalizes Rights Issue with Runway Extended to Late 2025 PDF Report Presentation Webcast
Regulatory 2024-08-14 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 14 August 2024 PDF Report Presentation Webcast
Regulatory 2024-07-10 | Notice of Extraordinary General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
2024-05-07 | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Patients PDF Report Presentation Webcast
Regulatory 2024-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024 PDF Report Presentation Webcast
Regulatory 2024-05-02 | Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
2024-04-18 | Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility PDF Report Presentation Webcast